Esperion (ESPR) has entered into a settlement agreement with Accord Healthcare. This agreement resolves the patent litigation brought by Esperion against Accord Healthcare in response to Accord Healthcare’s Abbreviated New Drug Application seeking approval to market a generic version of Nexletol prior to the expiration of the applicable patents. Accord Healthcare has agreed not to market a generic version of Nexletol in the U.S. prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants – Alkem Laboratories; Aurobindo Pharma; Dr. Reddy’s Laboratories; MSN Pharmaceuticals; Renata Limited; and Sandoz – is ongoing.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion Expands Board with New Appointment
- Esperion appoints Craig Thompson to board of directors
- Esperion’s Strategic Growth and Global Expansion Drive Buy Rating
- Esperion participates in a conference call with Cantor Fitzgerald
- Esperion’s Strategic Positioning and Growth Potential: Legal Settlements and Market Expansion Drive Buy Rating